The estimated Net Worth of Allan Steven Jacobson is at least $3.23 million dollars as of 22 January 2024. Allan Jacobson owns over 10,000 units of PTC Therapeutics Inc stock worth over $721,170 and over the last 11 years he sold PTCT stock worth over $2,087,703. In addition, he makes $416,355 as Independent Director at PTC Therapeutics Inc.
Sign up
Allan Jacobson PTCT stock SEC Form 4 insiders trading
Allan has made over 9 trades of the PTC Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of PTCT stock worth $270,500 on 22 January 2024.
The largest trade he's ever made was exercising 23,000 units of PTC Therapeutics Inc stock on 11 May 2023 worth over $249,550. On average, Allan trades about 5,462 units every 180 days since 2014. As of 22 January 2024 he still owns at least 22,348 units of PTC Therapeutics Inc stock.
You can see the complete history of Allan Jacobson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Allan Jacobson biography
Dr. Allan S. Jacobson Ph.D. serves as Independent Director of the Company. Dr. Jacobson has served as a member of our Board since our inception in 1998, and previously served as Chairman of our Board from 1998 to 2004. Since 2000, Dr. Jacobson has served as Chairman of our scientific advisory board. Since 1994, Dr. Jacobson has been the Chairman of the Department of Microbiology and Physiological Systems at the University of Massachusetts Medical School. In 1982, Dr. Jacobson co-founded Applied bioTechnology, Inc., a biotechnology company, and served as its chairman until its sale in 1991. From 1987 to 1990, Dr. Jacobson served as special limited partner at Euclid Partners, a venture capital firm. Dr. Jacobson received a Ph.D. from Brandeis University in 1971, has authored over 100 publications in the field of post-transcriptional control processes and is an elected member of the American Academy of Microbiology. Jacobson is qualified to serve on our Board because of his service as one of our directors since our inception, his knowledge of our Company and his extensive experience as a founder and leader of new businesses in the life science industry.
What is the salary of Allan Jacobson?
As the Independent Director of PTC Therapeutics Inc, the total compensation of Allan Jacobson at PTC Therapeutics Inc is $416,355. There are 9 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of $7,759,440.
How old is Allan Jacobson?
Allan Jacobson is 74, he's been the Independent Director of PTC Therapeutics Inc since 1998. There are 2 older and 17 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
What's Allan Jacobson's mailing address?
Allan's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, 07080.
Insiders trading at PTC Therapeutics Inc
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel et Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
What does PTC Therapeutics Inc do?
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
What does PTC Therapeutics Inc's logo look like?
Complete history of Allan Jacobson stock trades at PTC Therapeutics Inc
PTC Therapeutics Inc executives and stock owners
PTC Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Stuart Peltz,
Chief Executive Officer, Director -
Neil Almstead,
Chief Technical Operations Officer -
Mark Boulding,
Executive Vice President, Chief Legal Officer -
Emily Hill,
Principal Financial Officer, Treasurer -
Dr. Stuart W. Peltz,
Co-Founder, CEO & Exec. Director -
Christine Utter,
Senior Vice President - Finance, Chief Accounting Officer -
Mark Elliott Boulding,
Exec. VP & Chief Legal Officer -
Dr. Neil Almstead,
Chief Technical Operations Officer -
Michael Schmertzler,
Independent Chairman of the Board -
Allan Jacobson,
Independent Director -
Emma Reeve,
Independent Director -
David Southwell,
Independent Director -
Dawn Svoronos,
Independent Director -
Glenn Steele,
Independent Director -
Jerome Zeldis,
Independent Director -
Stephanie Okey,
Independent Director -
Dr. Allan Steven Jacobson,
Independent Co-Founder, Chairman of Scientific Advisory Board & Director -
Eric Pauwels,
Chief Business Officer -
Matthew Klein,
Chief Development Officer -
Jane Baj,
VP of Corp. Communications -
Alex Kane,
Investor Relations Officer -
Ellen Welch Ph.D.,
Chief Scientific Officer -
Christine Utter,
Sr. VP, Chief Accounting Officer & Head of People Services -
Adam Koppel,
Director -
Cameron Geoffrey Mc Donough,
Director -
Tuyen Ong,
Chief Medical Officer -
Marcio Souza,
Chief Operating Officer -
Pharma Holdings Ii, Llc Com...,
10% owner -
Mark Rothera,
Chief Commercial Officer -
Ronald C Jr Renaud,
Director -
Suisse/ Credit,
-
Claudia De Oliveira Ribeiro...,
President -
Bioventures Cayman Ltd Hbm,
10% owner -
Robert J. Spiegel,
Chief Medical Officer -
Richard Aldrich,
Director -
Ventures Inc.Vulcan Capital...,
-
Shane William Charles Kovacs,
EVP, CFO & Head of Corp Dev -
Axel Bolte,
Director -
Michael L Kranda,
Director -
Pierre Gravier,
CHIEF FINANCIAL OFFICER -
Mary L. Smith,
-
William F. Jr. Bell,
-
Alethia Young,
-
Lee Scott Golden,
EVP & CHIEF MEDICAL OFFICER